TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10608399
Drug: MultiHance (gadobenate
Approvals — FDA: no, EMA: no, PMDA: no
Description: MultiHance (gadobenate dimeglumine, Gd‐BOPTA) administered at a dosage of 0.05 mmol/kg during the dynamic phase of contrast enhancement.
Study: 8719517
Drug: Engerix-B (EB)
Normalized name: Engerix-B
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engerix-B (EB) 20 micrograms administered IM at 0, 1, 2, and 12 months
Study: 8719517
Drug: Recombivax HB
Normalized name: Recombivax HB
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombivax HB (RHB) 10 micrograms administered IM at 0, 1, and 6 months
Study: 1837245
Drug: Niaprazine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niaprazine (1 mg/kg body weight)
Study: 30417225
Drug: 14-day treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14-day treatment with 10% carbamide peroxide gel applied for 2 hours a day
Study: 30417225
Drug: 21-day treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 21-day treatment with 10% carbamide peroxide gel applied for 2 hours a day
Study: 23127291
Drug: Intranasal azelastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal azelastine (AZE; 137 μg/spray)
Study: 23127291
Drug: Intranasal fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal fluticasone propionate (FP; 50 μg/spray)
Study: 15020607
Drug: Trastuzumab alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab alone or combined with palliative radiotherapy or hormonal therapy
Study: 11842886
Drug: Phosphatidylserine (PS)
Normalized name: Phosphatidylserine
DrugBank: Phosphatidyl serine (DB00144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphatidylserine (PS) supplementation 300 mg daily for one month
Study: 3058016
Drug: HPA-23 (ammonium-21-tungsto-9-antimoniate)
Normalized name: ammonium chloride / antimony potassium tartrate / ipecac
DrugBank: HPA-23 (DB17739)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPA-23 (ammonium-21-tungsto-9-antimoniate) at 0.25, 0.5, 1.0, or 2.0 mg/kg intravenously 5 days per week for 8 weeks
Study: 21982727
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets (three times daily)
Study: 18775597
Drug: Intravaginal metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal metronidazole (2x 1000 mg pessaries 24h apart)
Study: 18775597
Drug: Oral metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metronidazole (1 x 2000 mg tablets)
Study: 12872393
Drug: CT positioning
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT positioning scalp circum-needling (SCN) combined with Chinese herbal medicine (Fuyuan mixture)
Study: 1947469
Drug: High-dose cytosine
Normalized name: cytosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytosine arabinoside combined with dexamethasone and cisplatinum
Study: 1947469
Drug: Low-dose cytosine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cytosine arabinoside combined with dexamethasone and cisplatinum
Study: 31389731
Drug: Cyclosporin 4
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin 4 mg/kg/d for 3 months
Study: 27193374
Drug: Allergen-specific immunotherapy
Normalized name: Pacific halibut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen-specific immunotherapy (ASIT)
Study: 25037883
Drug: Subcutaneous growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous growth hormone injection (3 mg/24 h) during exercise (1 hour bicycling with 50 W load)
Study: 25037883
Drug: Subcutaneous growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous growth hormone injection (3 mg/24 h) during supine rest
Study: 25037883
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous growth hormone infusion (3 mg/24 h)
Study: 16804691
Drug: Low alcohol
Normalized name: Low alcohol beer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low alcohol dose (two to three drinks equivalent)
Study: 16804691
Drug: High alcohol
Normalized name: High alcohol lager
Approvals — FDA: no, EMA: no, PMDA: no
Description: High alcohol dose (four to five drinks equivalent)
Study: 10714423
Drug: Inhaled glucocorticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled glucocorticosteroids (IGC), 250 microg of fluticasone propionate (FP) twice a day for 8 weeks
Study: 10714423
Drug: Inhaled glucocorticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled glucocorticosteroids (IGC)
Study: 8881621
Drug: Propofol 3‐5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 3‐5 mg kg‐1 h‐1 i.v.
Study: 3884128
Drug: Doxorubicin (A)
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (A) 60 mg/m2
Study: 3884128
Drug: Doxorubicin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 60 mg/m2 and cyclophosphamide 500 mg/m2 (CA)
Study: 3884128
Drug: Doxorubicin (A)
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (A) 60 mg/m2 and Doxorubicin 60 mg/m2 and cyclophosphamide 500 mg/m2 (CA)
Study: 30198644
Drug: Inhaled desflurane
Normalized name: desflurane Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled desflurane
Study: 25435604
Drug: Diabegon (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabegon (4 gm daily)
Study: 23059927
Drug: ASA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA therapy suspended for seven days before tooth extraction
Study: 23059927
Drug: ASA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA therapy continued without suspension
Study: 10599711
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment (GH) discontinued after 2 years
Study: 1769866
Drug: Ems brine
Normalized name: brine shrimp extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ems brine inhalations (200 ml, 3 times a day for 10 days)
Study: 1769866
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (200 ml, 3 times a day for 10 days)
Study: 6155131
Drug: Pseudoephedrine 180
Normalized name: fexofenadine-pseudoephedrine 180 mg-240 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoephedrine 180 mg
Study: 31335881
Drug: TNF inhibitor
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF inhibitor alone (n = 25)
Study: 31335881
Drug: TNF inhibitor
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF inhibitor combined with methotrexate (MTX) (n = 10)
Study: 31335881
Drug: MTX monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX monotherapy (n = 16)
Study: 11234182
Drug: Weekly home
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly home fructosamine monitoring in addition to daily glucose monitoring
Study: 11234182
Drug: Daily glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily glucose monitoring only (Control)
Study: 15034317
Drug: UDCA (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA (600 mg/day for 12 months)
Study: 3706881
Drug: Intravenously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously administered aminophylline (17.0 to 22.4 mg/L)
Study: 3706881
Drug: Intravenously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously administered aminophylline plus inhaled isoproterenol
Study: 3706881
Drug: Intravenously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously administered placebo
Study: 15918560
Drug: Chemotherapy and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and/or radiotherapy
Study: 11909787
Drug: Optimised insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Optimised insulin injections
Study: 12377361
Drug: Four-session guided
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-session guided self-change treatment
Study: 12377361
Drug: One-session advice
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-session advice treatment
Study: 9846012
Drug: Response-oriented individualized
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Response-oriented individualized induction therapy with six drugs (doxorubicin, mitoxantrone, vincristine, prednisolone, cyclophosphamide, L-asparaginase)
Study: 9846012
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with leukocytes < 30,000/microliter and blasts < 10% on day 15
Study: 7854594
Drug: 0.5 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml/kg ethanol
Study: 2509264
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment (sodium valproate or phenobarbitone)
Study: 807007
Drug: Parenteral 1.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral 1.75 per cent L‐essential amino acids in 47 per cent dextrose (Group I)
Study: 28318451
Drug: Bacterial lysate
Normalized name: Thermus thermophilus lysate
DrugBank: Thermus thermophilus lysate (DB11227)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacterial lysate administered 10 days per month for 3 months
Study: 16485883
Drug: 3% diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% diclofenac sodium gel used for 90 days
Study: 16485883
Drug: 5% 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% 5-fluorouracil cream used for 28 days
Study: 15344544
Drug: Endoscopic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic treatment (methods include Endoluminal Gastroplication, Full Thickness Plicator, Stretta, Enteryx, Gatekeeper)
Study: 15344544
Drug: Medication and
Normalized name: CVS Health Medication and Topical Refill Pouch KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication and laparoscopic antireflux surgery
Study: 10645920
Drug: High antibody
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High antibody levels to herpes simplex type I (HSV‐1)
Study: 10645920
Drug: High antibody
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High antibody levels to Chlamydia pneumoniae (Cpn)
Study: 10645920
Drug: Joint effect
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Joint effect of high antibody levels to HSV‐1 and Cpn
Study: 10645920
Drug: Low antibody
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low antibody levels and low CRP
Study: 1606999
Drug: Amitriptyline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (50 mg and 100 mg)
Study: 8436156
Drug: Amoxapine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxapine (100 mg and 200 mg)
Study: 30699060
Drug: Pazufloxacin 0.6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazufloxacin 0.6% ophthalmic solution (BID, n = 90)
Study: 30699060
Drug: Pazufloxacin 0.6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazufloxacin 0.6% ophthalmic solution (TID, n = 76)
Study: 30699060
Drug: Pazufloxacin 0.6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazufloxacin 0.6% ophthalmic solution (QID, n = 68)
Study: 23391599
Drug: Prophylactic paracetamol
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic paracetamol (PP) group
Study: 23391599
Drug: Non-prophylactic paracetamol
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-prophylactic paracetamol (NPP) group
Study: 17477886
Drug: Agomelatine 25
Normalized name: Agomelatine 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine 25 mg/d for 42 days
Study: 14977803
Drug: Rofecoxib 50
Normalized name: rofecoxib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 50 mg p.o. preoperatively followed by placebo
Study: 14977803
Drug: Diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 50 mg p.o. (three doses)
Study: 9786475
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses of DW-116 (100, 200, 300, and 800 mg)
Study: 9786475
Drug: Multiple oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple oral doses of DW-116 (300 mg for 7 days)
Study: 9786475
Drug: Multiple oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple oral doses of DW-116 (400 mg for 7 days)
Study: 9786475
Drug: Single and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single and multiple dosing of DW-116
Study: 8147929
Drug: Intraarticular injections
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular injections of hyaluronan (2.5 ml, weekly for 5 weeks)
Study: 31664765
Drug: Cariprazine 4.5
Normalized name: cariprazine 4.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariprazine 4.5 mg/day
Study: 31664765
Drug: Cariprazine (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariprazine (dose range 1.5-6 mg/day for schizophrenia and 3-6 mg/day for bipolar mania)
Study: 31664765
Drug: Cariprazine (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariprazine (dose increase)
Study: 18617483
Drug: Baseline NT-pro-BNP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline NT-pro-BNP ≥ 9252 pg/mL (fourth quartile)
Study: 11531681
Drug: ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 4 mg (2 mg.ml‐1 solution) diluted into a 5‐ml solution
Study: 11531681
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg lidocaine (5 ml 1% solution)
Study: 11531681
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml of intravenous 0.9% sodium chloride solution (placebo)
Study: 3155379
Drug: Vaccinia melanoma
Normalized name: vaccinia virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccinia melanoma oncolysate (VMO) at higher doses (1.5 and 2.0 mg) with immediate treatment schedule
Study: 3155379
Drug: Vaccinia melanoma
Normalized name: vaccinia virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccinia melanoma oncolysate (VMO) with delayed treatment schedule
Study: 3155379
Drug: Anti-HLA antibody
Normalized name: Anti-HLA antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-HLA antibody and circulating immune complexes
Study: 31774306
Drug: Intragastric quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intragastric quinine 600 mg (Q600)
Study: 31774306
Drug: Intragastric quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intragastric quinine 275 mg (Q275)
Study: 23435143
Drug: Dai-kenchu-to (DKT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dai-kenchu-to (DKT) 2.5 g administered orally three times a day from postoperative day (POD) 1
Study: 19812935
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate infusion (n = 6)
Study: 19812935
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion (n = 6)
Study: 12554899
Drug: Pigtail drainage
Normalized name: PLEURX DRAINAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pigtail drainage combined with anti-TB drug treatment
Study: 12554899
Drug: Only anti-TB
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only anti-TB drugs
Study: 11054390
Drug: Interferon-ribavirin combination
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Interferon-ribavirin combination therapy for 24 weeks
Study: 11054390
Drug: Interferon-ribavirin combination
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Interferon-ribavirin combination therapy for 48 weeks
Study: 1323324
Drug: ACTH (1
Normalized name: SNP-ACTH (1-39)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTH (1 mg i.m. in long-acting form)
Study: 31841498
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg daily vitamin D supplementation
Study: 31841498
Drug: 30 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg daily vitamin D supplementation
Study: 29883188
Drug: Standard analgesic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard analgesic care (Control)
Study: 26519116
Drug: Bi-weekly rotation
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bi-weekly rotation exercise classes (n=20)
Study: 20199846
Drug: Goal-setting strategy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goal-setting strategy (mental contrasting), cognitive behavioral therapy-oriented problem-solving approach, goal-pursuit strategy (implementation intentions)
Study: 18018417
Drug: Switch therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch therapy (injectable quinolone switched to oral quinolone)
Study: 18018417
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of carbapenem antibacterial agent
Study: 16287366
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (CM; 0.3 g.kg(‐1).day(‐1) + 20 g Polycose)
Study: 10444418
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (0.25, 0.50, and 1 mU.kg(‐1).min(‐1)) in healthy controls
Study: 10444418
Drug: Insulin deprivation
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin deprivation or insulin replacement in type 1 diabetic subjects
Study: 7816064
Drug: Methotrexate (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (25 mg once weekly)
Study: 31149870
Drug: AS03-adjuvanted multicomponent
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03-adjuvanted multicomponent vaccine (CPS5/CPS8/α-toxin/ClfA)
Study: 31149870
Drug: Non-adjuvanted multicomponent
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted multicomponent vaccine (CPS5/CPS8/α-toxin/ClfA)
Study: 26813473
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment plus trimetazidine hydrochloride for 6 months
Study: 24171895
Drug: Acupuncture with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture with NSAIDs (zaltoprofen, 80 mg daily)
Study: 12233877
Drug: Anti-TNF-α therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF-α therapy
Study: 19188654
Drug: Oral Syringe
Normalized name: Oral Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Syringe
Study: 12492742
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lanzoprazole 30 mg, clarithromycin OD 500 mg, and furazolidone 400 mg, once daily for 7 days (Group A)
Study: 12492742
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lanzoprazole 30 mg, clarithromycin OD 500 mg, and furazolidone 200 mg, once daily for 7 days (Group B)
Study: 10831005
Drug: Fexofenadine HCl
Normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine HCl 20 mg
Study: 9433370
Drug: Fexofenadine HCl
Normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine HCl 60 mg
Study: 10831005
Drug: Fexofenadine HCl
Normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine HCl 240 mg
Study: 23428652
Drug: Multidisciplinary weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Multidisciplinary weekly family‐based behavioral group delivered via telemedicine
Study: 18420096
Drug: CoStar drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoStar drug-eluting stent (DES)
Study: 18420096
Drug: Taxus drug-eluting
Normalized name: Taxus baccata fruit extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxus drug-eluting stent (DES)
Study: 13129448
Drug: Beta-cryptoxanthin esters
Normalized name: lutein esters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-cryptoxanthin esters from papaya (1.3 mg)
Study: 13129448
Drug: Non-esterified beta-cryptoxanthin
Normalized name: Esterified Estrogens
DrugBank: Esterified estrogens (DB09381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-esterified beta-cryptoxanthin (1.3 mg)
Study: 10815894
Drug: Antivascular endothelial
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antivascular endothelial growth factor antibodies
Study: 9028752
Drug: Rectal indomethacin
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal indomethacin 100 mg
Study: 9028752
Drug: Intravenous pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous pethidine alone
Study: 1667648
Drug: Dietary fibre
Normalized name: Fiore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary fibre supplementation (wheat fibre and ispaghula) at an average intake of 16 g per day for six months
Study: 6219156
Drug: Inhaled ipratropium
Normalized name: ipratropium Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled ipratropium plus oral oxtriphylline